Anthony Mancini, Revolution Medicines, Inc. (NASDAQ:RVMD) Chief Global Commercialization Officer, completed a set of stock transactions on March 25, 2026, selling 26,552 shares of the company's common stock for approximately $3.5 million. The disposals occurred across multiple trades at prices ranging from $93.223 to $97.2071 per share.
In parallel with the sales, Mancini exercised stock options to purchase 37,450 shares of Revolution Medicines common stock at an exercise price of $33.62, for a total cost of $1259069. The dispositions were carried out under a 10b5-1 trading plan that Mancini established on December 24, 2025.
After these actions, Mancini directly holds 54,400 Restricted Stock Units and a total of 54,400 shares of Revolution Medicines common stock.
The company's shares have experienced considerable appreciation recently, rising 145% over the past year and 112% over the prior six months. Despite those gains, InvestingPro analysis included in company coverage indicates that the shares appear overvalued relative to InvestingPro's Fair Value assessment, ranking RVMD among the most overvalued stocks in the market according to that metric.
Operationally, Revolution Medicines reported fourth-quarter 2025 results that showed a net loss per share of negative $1.86, wider than the consensus estimate of negative $1.58. The miss was attributed to higher-than-expected research and development spending as well as elevated selling, general, and administrative costs. At the end of the quarter the company reported $2.03 billion in cash and investments, a cash position the company said was supported by a strategic partnership with Royalty Pharma.
Analyst coverage and price-target moves followed the quarter. UBS initiated coverage of Revolution Medicines with a Buy rating, citing the clinical efficacy of its RAS inhibitors across multiple solid tumor indications. Piper Sandler raised its price target on the stock to $120 and maintained an Overweight rating, noting confidence in the companys drug-development trajectory. Needham adjusted its price target to $145 from $150 but maintained a Buy rating despite calling out rising costs as a concern. Wells Fargo increased its price target to $144 and flagged clinical-trial progress, expressing confidence in the potential for daraxon in pancreatic ductal adenocarcinoma.
InvestingPro subscribers are offered additional analysis including 12 supplementary ProTips and Pro Research Reports covering more than 1,400 U.S. equities. Separately, ProPicks AI evaluates RVMD alongside thousands of other companies each month using over 100 financial metrics to identify risk-reward opportunities based on current data. The ProPicks AI program lists past winners that include Super Micro Computer (+185%) and AppLovin (+157%).
These developments - insider selling under a pre-established trading plan, option exercises, a quarterly earnings shortfall, a strong cash position, and active analyst updates - collectively frame the current investor and analyst focus on Revolution Medicines as the company advances its clinical programs and manages rising costs.